Dietary Methyl Deficiency, MicroRNA Expression and Susceptibility to Liver Carcinogenesis

Overview

Journal J Nutrigenet Nutrigenomics

Publisher Karger

Specialties Genetics
Nutritional Sciences

Date 2011 Apr 9

PMID 21474957

Citations 4

Authors

Athena Starlard-Davenport

Volodymyr Tryndyak

Oksana Kosyk

Sharon R Ross

Ivan Rusyn

Frederick A Beland

Igor P Pogribny

Affiliations

Soon will be listed here.

Citing Articles

Deciphering the role of aberrant DNA methylation in NAFLD and NASH.

Vachher M, Bansal S, Kumar B, Yadav S, Burman A Heliyon. 2022; 8(10):e11119.

PMID: 36299516 PMC: 9589178. DOI: 10.1016/j.heliyon.2022.e11119.

Maternal methyl donors supplementation during lactation prevents the hyperhomocysteinemia induced by a high-fat-sucrose intake by dams.

Cordero P, Milagro F, Campion J, Martinez J Int J Mol Sci. 2013; 14(12):24422-37.

PMID: 24351826 PMC: 3876120. DOI: 10.3390/ijms141224422.

Epigenetic events in liver cancer resulting from alcoholic liver disease.

French S Alcohol Res. 2013; 35(1):57-67.

PMID: 24313165 PMC: 3860418.

Dietary supplementation with methyl donors reduces fatty liver and modifies the fatty acid synthase DNA methylation profile in rats fed an obesogenic diet.

Cordero P, Gomez-Uriz A, Campion J, Milagro F, Martinez J Genes Nutr. 2012; 8(1):105-13.

PMID: 22648174 PMC: 3534997. DOI: 10.1007/s12263-012-0300-z.

References

Ma L, Teruya-Feldstein J, Weinberg R . Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007; 449(7163):682-8. DOI: 10.1038/nature06174. View

Farrell G, Larter C . Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006; 43(2 Suppl 1):S99-S112. DOI: 10.1002/hep.20973. View

Anstee Q, Goldin R . Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol. 2006; 87(1):1-16. PMC: 2517349. DOI: 10.1111/j.0959-9673.2006.00465.x. View

Guarnieri D, DiLeone R . MicroRNAs: a new class of gene regulators. Ann Med. 2008; 40(3):197-208. DOI: 10.1080/07853890701771823. View

Sung Y, Hwang S, Kim J, Bae H, Kim J, Kim M . The correlation between cyclooxygenase-2 expression and hepatocellular carcinogenesis. Mol Cells. 2004; 17(1):35-8. View

Denda A, Kitayama W, Murata A, Kishida H, Sasaki Y, Kusuoka O . Increased expression of cyclooxygenase-2 protein during rat hepatocarcinogenesis caused by a choline-deficient, L-amino acid-defined diet and chemopreventive efficacy of a specific inhibitor, nimesulide. Carcinogenesis. 2002; 23(2):245-56. DOI: 10.1093/carcin/23.2.245. View

Farrell G, Larter C, Hou J, Zhang R, Yeh M, Williams J . Apoptosis in experimental NASH is associated with p53 activation and TRAIL receptor expression. J Gastroenterol Hepatol. 2009; 24(3):443-52. DOI: 10.1111/j.1440-1746.2009.05785.x. View

Aqeilan R, Calin G, Croce C . miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ. 2009; 17(2):215-20. DOI: 10.1038/cdd.2009.69. View

Gramantieri L, Fornari F, Callegari E, Sabbioni S, Lanza G, Croce C . MicroRNA involvement in hepatocellular carcinoma. J Cell Mol Med. 2009; 12(6A):2189-204. PMC: 4514099. DOI: 10.1111/j.1582-4934.2008.00533.x. View

10.

Bartel D . MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-97. DOI: 10.1016/s0092-8674(04)00045-5. View

11.

Calin G, Croce C . MicroRNA signatures in human cancers. Nat Rev Cancer. 2006; 6(11):857-66. DOI: 10.1038/nrc1997. View

12.

Yamanaka Y, Tagawa H, Takahashi N, Watanabe A, Guo Y, Iwamoto K . Aberrant overexpression of microRNAs activate AKT signaling via down-regulation of tumor suppressors in natural killer-cell lymphoma/leukemia. Blood. 2009; 114(15):3265-75. DOI: 10.1182/blood-2009-06-222794. View

13.

Mott J . MicroRNAs involved in tumor suppressor and oncogene pathways: implications for hepatobiliary neoplasia. Hepatology. 2009; 50(2):630-7. PMC: 2721015. DOI: 10.1002/hep.23010. View

14.

Lin C, Gong H, Tseng H, Wang W, Wu J . miR-122 targets an anti-apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines. Biochem Biophys Res Commun. 2008; 375(3):315-20. DOI: 10.1016/j.bbrc.2008.07.154. View

15.

Zheng T, Wang J, Chen X, Liu L . Role of microRNA in anticancer drug resistance. Int J Cancer. 2009; 126(1):2-10. DOI: 10.1002/ijc.24782. View

16.

Ventura A, Jacks T . MicroRNAs and cancer: short RNAs go a long way. Cell. 2009; 136(4):586-91. PMC: 3910108. DOI: 10.1016/j.cell.2009.02.005. View

17.

Pogribny I, Tryndyak V, Boyko A, Rodriguez-Juarez R, Beland F, Kovalchuk O . Induction of microRNAome deregulation in rat liver by long-term tamoxifen exposure. Mutat Res. 2007; 619(1-2):30-7. DOI: 10.1016/j.mrfmmm.2006.12.006. View

18.

Kato M, Paranjape T, Muller R, Ullrich R, Nallur S, Gillespie E . The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cells. Oncogene. 2009; 28(25):2419-24. PMC: 2941141. DOI: 10.1038/onc.2009.106. View

19.

Mitsuyoshi H, Yasui K, Harano Y, Endo M, Tsuji K, Minami M . Analysis of hepatic genes involved in the metabolism of fatty acids and iron in nonalcoholic fatty liver disease. Hepatol Res. 2008; 39(4):366-73. DOI: 10.1111/j.1872-034X.2008.00464.x. View

20.

Gramantieri L, Fornari F, Ferracin M, Veronese A, Sabbioni S, Calin G . MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin Cancer Res. 2009; 15(16):5073-81. PMC: 3900721. DOI: 10.1158/1078-0432.CCR-09-0092. View